NO20043116L - Amidderivater som GK-aktivatorer - Google Patents
Amidderivater som GK-aktivatorerInfo
- Publication number
- NO20043116L NO20043116L NO20043116A NO20043116A NO20043116L NO 20043116 L NO20043116 L NO 20043116L NO 20043116 A NO20043116 A NO 20043116A NO 20043116 A NO20043116 A NO 20043116A NO 20043116 L NO20043116 L NO 20043116L
- Authority
- NO
- Norway
- Prior art keywords
- activators
- amide derivatives
- amide
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38618501P | 2001-12-21 | 2001-12-21 | |
EP02388015A EP1336607A1 (fr) | 2002-02-19 | 2002-02-19 | Dérivés d'amides comme activateus de la glucokinase |
PCT/DK2002/000880 WO2003055482A1 (fr) | 2001-12-21 | 2002-12-19 | Derives amide utiles en tant qu'activateurs de la glucokinase |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20043116L true NO20043116L (no) | 2004-09-20 |
Family
ID=26077624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20043116A NO20043116L (no) | 2001-12-21 | 2004-07-20 | Amidderivater som GK-aktivatorer |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030171411A1 (fr) |
EP (2) | EP2305648A1 (fr) |
JP (2) | JP2005518391A (fr) |
KR (1) | KR101018318B1 (fr) |
CN (1) | CN100506807C (fr) |
AU (1) | AU2002351748B2 (fr) |
BR (1) | BR0215212A (fr) |
CA (1) | CA2471049A1 (fr) |
CZ (1) | CZ2004747A3 (fr) |
HU (1) | HUP0402309A3 (fr) |
IL (1) | IL162620A0 (fr) |
MX (1) | MXPA04006048A (fr) |
NO (1) | NO20043116L (fr) |
PL (1) | PL370989A1 (fr) |
RU (1) | RU2374236C2 (fr) |
UA (1) | UA84390C2 (fr) |
WO (1) | WO2003055482A1 (fr) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
WO2003078448A1 (fr) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation de la methylation de proteines et du phosphate des phosphoproteines |
WO2004002481A1 (fr) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Activateurs de la glycokinase |
RU2340605C2 (ru) | 2002-06-27 | 2008-12-10 | Ново Нордиск А/С | Арилкарбонильные производные в качестве терапевтических средств |
CA2498089A1 (fr) * | 2002-10-03 | 2004-06-17 | Novartis Ag | Sulfamide ou amide a substitution (thiazol-2-yl) utile en tant qu'activateur de glycokinase dans le traitement du diabete de type 2 |
GB0226930D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
WO2004063194A1 (fr) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Composes heteroaryle |
JP4621198B2 (ja) * | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | トリ(シクロ)置換アミドグルコキナーゼ活性化化合物 |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
EP1608317B1 (fr) | 2003-03-25 | 2012-09-26 | Takeda Pharmaceutical Company Limited | Inhibiteurs de dipeptidyle peptidase |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7470700B2 (en) | 2003-08-13 | 2008-12-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
RU2392275C2 (ru) | 2004-02-18 | 2010-06-20 | Астразенека Аб | Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AU2004318013B8 (en) | 2004-03-15 | 2011-10-06 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
AP2379A (en) | 2004-03-23 | 2012-03-08 | Pfizer Prod Inc | Imidazole compounds for the treatment of neurodegenerative disorders. |
US7781451B2 (en) | 2004-04-02 | 2010-08-24 | Novartis Ag | Thiazolopyridine derivatives, pharmaceut ical conditions containing them and methods of treating glucokinase mediated conditions |
ATE524479T1 (de) | 2004-04-02 | 2011-09-15 | Novartis Ag | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren |
JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
WO2006019965A2 (fr) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Inhibiteurs de la dipeptidyl peptidase |
JP2008524331A (ja) * | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
WO2006084033A1 (fr) | 2005-02-03 | 2006-08-10 | Signum Biosciences, Inc. | Compositions et procedes pour l'amelioration de la fonction cognitive |
JP2009500378A (ja) * | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー/エス | グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素 |
JP2009500377A (ja) * | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー/エス | ジシクロアルキルウレア型グルコキナーゼ活性化剤 |
KR101346902B1 (ko) | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
US7884210B2 (en) | 2005-07-14 | 2011-02-08 | Novo Nordisk A/S | Ureido-thiazole glucokinase activators |
JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
CA2622472C (fr) | 2005-09-14 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
RS20080139A (en) | 2005-09-22 | 2009-05-06 | Pfizer Products Inc., | Imidazole coumpounds for the treatment of neurological disorders |
WO2007039177A2 (fr) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques |
GT200600428A (es) | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
CN101316837A (zh) * | 2005-11-01 | 2008-12-03 | 詹森药业有限公司 | 作为葡萄糖激酶变构调节剂的取代的吡咯酮类 |
EP1960385A1 (fr) | 2005-11-01 | 2008-08-27 | Janssen Pharmaceutica N.V. | Dihydroisoindolones substitutées modulateurs utilisées en tant que allostériques de la glucokinase |
CA2627910A1 (fr) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Cycloalkylpyrrolones substitues utilises en tant que modulateurs allosteriques de glucokinase |
WO2007053662A1 (fr) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Dihydroisoindolones utilisées comme modulateurs allostériques de la glucokinase |
KR20150041174A (ko) | 2005-11-08 | 2015-04-15 | 버텍스 파마슈티칼스 인코포레이티드 | Atp 결합 카세트 수송체의 헤테로사이클릭 조정제 |
EP1948614A2 (fr) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Activateurs de la glucokinase |
CA2632030A1 (fr) | 2005-12-15 | 2007-06-21 | Boehringer Ingelheim International Gmbh | Composes qui modulent le recepteur cb2 |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP1987028A2 (fr) | 2006-02-10 | 2008-11-05 | Transtech Pharma, Inc. | Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora |
JP5302012B2 (ja) | 2006-03-08 | 2013-10-02 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤 |
WO2007112347A1 (fr) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyl peptidase |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
CA2869945C (fr) | 2006-04-07 | 2018-01-23 | Vertex Pharmaceuticals Incorporated | Modulateurs des transporteurs de cassettes de liaison de l'atp |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
WO2007143434A2 (fr) | 2006-05-31 | 2007-12-13 | Takeda San Diego, Inc. | Activateurs de glucokinase |
JP5448164B2 (ja) | 2006-07-28 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を変調する化合物 |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US7928123B2 (en) | 2006-09-25 | 2011-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
US20080107725A1 (en) * | 2006-10-13 | 2008-05-08 | Albano Antonio A | Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers |
WO2008050600A1 (fr) * | 2006-10-25 | 2008-05-02 | Neugen Pharma Inc. | Agent thérapeutique ou préventif pour des maladies réfractaires, basé sur la mort cellulaire induite par le stress oxydatif en tant que contexte moléculaire |
TW200825060A (en) | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
EP2091947A2 (fr) * | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Activateurs de glucokinase |
JP2010515701A (ja) * | 2007-01-09 | 2010-05-13 | ノボ・ノルデイスク・エー/エス | ウレアグルコキナーゼアクチベーター |
EP2105435A4 (fr) * | 2007-01-10 | 2011-06-15 | Mitsubishi Tanabe Pharma Corp | Dérivé d'hydrazone |
JP5226008B2 (ja) * | 2007-01-11 | 2013-07-03 | ノボ・ノルデイスク・エー/エス | ウレアグルコキナーゼアクチベーター |
JP5491871B2 (ja) | 2007-02-28 | 2014-05-14 | アドビナス セラピュティックス プライベート リミテッド | グルコキナーゼ活性化因子としての2,2,2−三置換アセトアミド誘導体、その方法及び薬学的応用 |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
AU2008251504B2 (en) | 2007-05-09 | 2013-07-18 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
US8501955B2 (en) | 2007-10-08 | 2013-08-06 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal application |
US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
CN101821264A (zh) * | 2007-10-09 | 2010-09-01 | 默克专利有限公司 | 可用作葡萄糖激酶激活剂的吡啶衍生物 |
DK2639224T3 (en) | 2007-12-07 | 2016-10-17 | Vertex Pharma | A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer |
EP3170818B1 (fr) | 2007-12-07 | 2020-02-19 | Vertex Pharmaceuticals Incorporated | Formes solides d'acide benzoïque 3-(6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) |
WO2009108657A2 (fr) | 2008-02-28 | 2009-09-03 | Vertex Pharmaceuticals Incorporated | Dérivés hétéroaryles convenant comme modulateurs du cftr |
US8258134B2 (en) * | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
AU2009239430B2 (en) | 2008-04-21 | 2015-01-22 | Signum Biosciences, Inc. | Compounds, compositions and methods for making the same |
MX2010012298A (es) | 2008-05-16 | 2011-03-15 | Takeda San Diego Inc | Activadores de glucocinasa. |
RS57591B1 (sr) | 2008-06-19 | 2018-11-30 | Takeda Pharmaceuticals Co | Heterociklično jedinjenje i njegova upotreba |
AP2011005674A0 (en) | 2008-09-25 | 2011-04-30 | Boehringer Ingelheim Int | Sulfonyl compounds which selectively modulate the CB2 receptor. |
AU2009307884B2 (en) | 2008-10-22 | 2014-07-31 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
CA2757084C (fr) | 2009-03-30 | 2017-08-29 | Transtech Pharma, Inc. | Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation |
US20120088800A1 (en) * | 2009-06-30 | 2012-04-12 | Allergan, Inc. | 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS |
US20110021570A1 (en) | 2009-07-23 | 2011-01-27 | Nancy-Ellen Haynes | Pyridone glucokinase activators |
WO2011080755A1 (fr) | 2009-12-29 | 2011-07-07 | Advinus Therapeutics Private Limited | Composés hétérocycliques azotés condensés, leur procédé de préparation et leurs utilisations |
EP2523936A1 (fr) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Composés qui modulent le récepteur cb2 |
WO2011095997A1 (fr) | 2010-02-08 | 2011-08-11 | Advinus Therapeutics Private Limited | Composés de benzamide à titre d'activateurs de glucokinase et leur application pharmaceutique |
WO2011106273A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
HUE056525T2 (hu) | 2010-04-07 | 2022-02-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása |
WO2011130459A1 (fr) | 2010-04-14 | 2011-10-20 | Bristol-Myers Squibb Company | Nouveaux activateurs de la glucokinase et méthodes d'utilisation desdits activateurs |
MX2012012204A (es) | 2010-04-22 | 2012-12-05 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
EP2402327B1 (fr) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Composés d'acétamide en tant qu'activateurs de la glucokinase, leur procédé et applications médicales |
EP2595959B1 (fr) | 2010-07-22 | 2015-11-04 | Boehringer Ingelheim International GmbH | Composés sulfonylés qui modulent le récepteur cb2 |
CA2819381A1 (fr) | 2010-10-13 | 2012-04-19 | Takeda California, Inc. | Procede de preparation de derives d'azaindazole |
CA2822017C (fr) | 2010-12-23 | 2015-04-07 | Pfizer Inc. | Modulateurs du recepteur du glucagon |
DK2673260T3 (en) | 2011-02-08 | 2016-10-10 | Pfizer | Glucagonreceptormodulator |
US8796258B2 (en) | 2011-02-25 | 2014-08-05 | Merck Sharp & Dohme Corp. | Cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
MX2014000855A (es) | 2011-07-22 | 2014-04-30 | Pfizer | Moduladores receptores de glucagon de quinolinilo. |
EP2781521A4 (fr) * | 2011-10-19 | 2015-03-04 | Kowa Co | Nouveau composé de spiroindoline, et agent thérapeutique le contenant |
AR092857A1 (es) | 2012-07-16 | 2015-05-06 | Vertex Pharma | Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas |
US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病二環式化合物 |
EP2970119B1 (fr) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
EP2803668A1 (fr) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
US10231932B2 (en) | 2013-11-12 | 2019-03-19 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
EP2878339A1 (fr) * | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | Antagonistes SIP3 |
CN110840847B (zh) | 2014-04-15 | 2022-07-29 | 沃泰克斯药物股份有限公司 | 用于治疗囊性纤维化跨膜传导调节因子介导的疾病的药物组合物 |
DK3221692T3 (da) | 2014-11-18 | 2021-08-23 | Vertex Pharma | Fremgangsmåde til udførsel af tests med høj kapacitet ved hjælp af højtryksvæskekromatografi |
AU2016288204B2 (en) * | 2015-06-30 | 2020-11-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and methods of use thereof |
EP3551176A4 (fr) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
EP3558298A4 (fr) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
US11147788B2 (en) * | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
KR20190113598A (ko) * | 2018-03-28 | 2019-10-08 | 한림제약(주) | 2-시아노피리미딘-4-일 카르바메이트 혹은 유레아 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
MX2020008905A (es) | 2018-06-12 | 2020-12-03 | Vtv Therapeutics Llc | Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. |
US20230265083A1 (en) * | 2020-08-10 | 2023-08-24 | Prelude Therapeutics Incorporated | Heterocycle CDK Inhibitors And Their Use Thereof |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152136A (en) * | 1958-10-30 | 1964-10-06 | Dow Chemical Co | Dinitroaroyl-nu-pyridyl amides |
US3067250A (en) * | 1959-01-26 | 1962-12-04 | Dow Chemical Co | 4-aryl, 1, 1-di propynyl-semicarbazides |
US3317534A (en) * | 1963-10-30 | 1967-05-02 | Chugai Pharmaceutical Co Ltd | Benzamidopyrimidines |
US3551442A (en) * | 1965-04-06 | 1970-12-29 | Pechiney Saint Gobain | Thiazole derivatives |
US4175081A (en) * | 1968-02-01 | 1979-11-20 | Mobil Oil Corporation | 5-Substituted thiadiazole ureas |
GB1266769A (fr) * | 1969-08-15 | 1972-03-15 | ||
US3682163A (en) * | 1970-09-18 | 1972-08-08 | Walter A Plummer | Snap-on orthopedic splint |
US3887709A (en) * | 1971-09-16 | 1975-06-03 | Zdzislaw Brzozowski | 2-Pyrazoline-1-carboxamide sulfonamide derivatives useful as hypoglycemic agents |
DE2151766C3 (de) | 1971-10-14 | 1981-03-19 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | N-Thiazolinyl-phenoxycarbonsäureamide |
US3862163A (en) * | 1971-10-14 | 1975-01-21 | Schering Ag | Phenoxycarboxylic acid amides |
US3874873A (en) * | 1972-03-27 | 1975-04-01 | Fmc Corp | Herbicidal compositions based on 1,2,3-thiadiazol-5-yl ureas |
IE38778B1 (en) * | 1973-02-02 | 1978-05-24 | Ciba Geigy | New 1,2,4-benzotriazine derivatives |
JPS5614643B2 (fr) * | 1973-07-02 | 1981-04-06 | ||
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
PL106114B1 (pl) * | 1976-12-31 | 1979-11-30 | Akad Medyczna | Sposob wytwarzania nowych n-(4-/2-/pirazolo-1-karbonamido/-etylo/-benzenosulfonylo)-mocznikow |
DE2712630A1 (de) * | 1977-03-23 | 1978-09-28 | Bayer Ag | 1,3,4-thiadiazol-2-yl-harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide |
DE2716324A1 (de) * | 1977-04-07 | 1978-10-12 | Schering Ag | 1,2,3-thiadiazol-3-in-5-yliden- harnstoffe, verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel mit wachstumsregulatorischer wirkung fuer pflanzen |
JPS6033109B2 (ja) * | 1977-04-28 | 1985-08-01 | 塩野義製薬株式会社 | 尿素誘導体の合成法 |
US4241072A (en) * | 1979-01-18 | 1980-12-23 | Merck & Co., Inc. | Substituted ureas and processes for their preparation |
US4265871A (en) | 1979-05-07 | 1981-05-05 | Allied Chemical Corporation | Purification of boron-containing sulfuric acid |
DE2928485A1 (de) * | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4694004A (en) * | 1984-07-09 | 1987-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
US4808722A (en) * | 1985-10-31 | 1989-02-28 | Fmc Corporation | Pyridinylurea N-oxide compounds and agricultural uses |
US5371086A (en) * | 1991-03-15 | 1994-12-06 | The Green Cross Corporation | Aminopyridine compounds |
JPH05294935A (ja) * | 1991-03-15 | 1993-11-09 | Green Cross Corp:The | アミノピリジン系化合物 |
CA2134359C (fr) * | 1992-05-28 | 1997-07-01 | Ernest S. Hamanaka | Nouveaux derives n-aryliques et n-heteroaryluree utilises comme inhibiteurs de l'acyl-coa : cholesterol acyltransferase |
US5849769A (en) * | 1994-08-24 | 1998-12-15 | Medivir Ab | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection |
US5556969A (en) * | 1994-12-07 | 1996-09-17 | Merck Sharp & Dohme Ltd. | Benzodiazepine derivatives |
WO1996040629A1 (fr) * | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Composes de type tyrphostine utilises pour le traitement de troubles de la proliferation cellulaire ou de troubles de la differenciation cellulaire |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
JP3043430B2 (ja) | 1995-09-08 | 2000-05-22 | ノボ ノルディスク アクティーゼルスカブ | 2−アルキルピロリジン類 |
JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
CN1158290C (zh) | 1996-01-17 | 2004-07-21 | 诺沃挪第克公司 | 稠合1,2,4-噻二嗪与稠合1,4-噻嗪衍生物、其制备方法及用途 |
CA2197364A1 (fr) * | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Compose phenolique et methode de preparation |
CN1221417A (zh) | 1996-07-26 | 1999-06-30 | 雷迪博士研究基金会 | 具有抗糖尿病、降低血脂、抗高血压性能的噻唑烷二酮化合物,其制备方法及其药物组合物 |
JP3149958B2 (ja) | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Glp―1誘導体 |
TW523506B (en) * | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
IL142649A (en) | 1996-12-31 | 2004-12-15 | Reddy Research Foundation | Azole derivatives |
US5846985A (en) * | 1997-03-05 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
EP0981526B1 (fr) | 1997-05-02 | 2004-02-25 | Dr. Reddy's Laboratories Ltd. | Nouveaux composes anti-diabetiques avec proprietes hypolipidemiantes et anti-hypertensives, procede pour les preparer et compositions pharmaceutiques contenant ces composes |
SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
BR9810378A (pt) | 1997-07-01 | 2000-08-29 | Novo Nordisk As | Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero |
PL338013A1 (en) | 1997-07-16 | 2000-09-25 | Novo Nordisk As | Derivatives of condensed 1,2,4-thiadiazine, their production and application |
US6268384B1 (en) * | 1997-08-29 | 2001-07-31 | Vertex Pharmaceuticals Incorporated | Compounds possessing neuronal activity |
US6225346B1 (en) * | 1997-10-24 | 2001-05-01 | Sugen, Inc. | Tyrphostin like compounds |
US6440961B1 (en) | 1997-10-27 | 2002-08-27 | Dr. Reddy's Research Foundation | Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them |
WO1999019313A1 (fr) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant |
DE69803750T2 (de) | 1997-12-02 | 2002-09-12 | Dr. Reddy's Research Foundation, Andhra Pradesh | Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften |
US6407124B1 (en) * | 1998-06-18 | 2002-06-18 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
WO2000023417A1 (fr) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
EP1123279A1 (fr) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation correspondantes |
JP2002527502A (ja) | 1998-10-21 | 2002-08-27 | ノボ ノルディスク アクティーゼルスカブ | 新規化合物、それらの調製及び使用 |
EP1123267A1 (fr) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | Nouveaux composes, preparation et utilisation correspondantes |
EP1123292A1 (fr) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
EP1123297A1 (fr) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
DE69908648T2 (de) | 1998-12-18 | 2004-05-13 | Novo Nordisk A/S | Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung |
WO2000041121A1 (fr) | 1999-01-07 | 2000-07-13 | Ccrewards.Com | Procede et dispositif d'emission et de gestion de bons numeriques et d'offres de vente |
WO2000042026A1 (fr) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Agonistes non peptidiques de glp-1 |
AU3033100A (en) | 1999-01-18 | 2000-08-01 | Boehringer Ingelheim International Gmbh | Substituted imidazoles, their preparation and use |
US6500817B1 (en) * | 1999-03-08 | 2002-12-31 | Bayer Aktiengesellschaft | Thiazolyl urea derivatives and their utilization as antiviral agents |
US6610846B1 (en) * | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
AU767830B2 (en) * | 1999-03-29 | 2003-11-27 | F. Hoffmann-La Roche Ag | Glucokinase activators |
AU3957800A (en) | 1999-04-16 | 2000-11-02 | Dr. Reddy's Research Foundation | Crystalline r- guanidines, arginine or (l) -arginine (2(s)) -2- ethoxy -3-(4- (2-(10(h) -phenoxazin -10-yl)ethoxy}phenyl)propanoate |
WO2000063191A1 (fr) | 1999-04-16 | 2000-10-26 | Dr. Reddy's Research Foundation | Nouvelles formes polymorphes d'un agent antidiabetique: procede de preparation et composition pharmaceutique contenant ces dernieres |
IL145958A0 (en) | 1999-04-16 | 2002-07-25 | Reddy Research Foundation | Polymorphic form of arginine salt of (2s)-3-[4-[2-phenoxazin-10-yl)ethoxy] phenyl]2-ethoxypropanoic acid, processes for the preparation thereof and pharmaceutical compositions containing the same |
WO2000063208A1 (fr) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Imidazoles substitues, leur preparation et utilisation |
WO2000063196A1 (fr) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | Nouveaux composes, leur preparation et leur utilisation |
JP2002542237A (ja) | 1999-04-20 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | 新規な化合物、それらの製造及び使用 |
AU3958100A (en) | 1999-04-20 | 2000-11-02 | Novo Nordisk A/S | New compounds, their preparation and use |
EP1171414A1 (fr) | 1999-04-20 | 2002-01-16 | Novo Nordisk A/S | Composes, preparation et utilisation de ces derniers |
AU3957600A (en) | 1999-04-26 | 2000-11-10 | Boehringer Ingelheim International Gmbh | Piperidyl-imidazole derivatives, their preparations and therapeutic uses |
US6503949B1 (en) * | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
JP3788935B2 (ja) * | 2000-05-03 | 2006-06-21 | エフ.ホフマン−ラ ロシュ アーゲー | アルキニルフェニルヘテロ芳香族グルコキナーゼ活性化物質 |
ATE304011T1 (de) | 2000-05-03 | 2005-09-15 | Hoffmann La Roche | Hydantoin-enthaltende glucokinase aktivatoren |
WO2001085706A1 (fr) * | 2000-05-08 | 2001-11-15 | F. Hoffmann-La Roche Ag | Phenylacetamides substitues et leur utilisation en tant qu'activateurs de la glucokinase |
EP1283830B1 (fr) | 2000-05-08 | 2008-06-18 | F. Hoffmann-La Roche Ag | Activateurs de glucokinase de type phenylamides substitues para-amine |
MXPA02012795A (es) * | 2000-06-28 | 2004-07-30 | Teva Pharma | Carvedilol. |
AU8760001A (en) * | 2000-07-20 | 2002-02-05 | Hoffmann La Roche | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
US6645990B2 (en) * | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
PL365443A1 (en) * | 2001-01-31 | 2005-01-10 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
ATE315555T1 (de) * | 2001-05-11 | 2006-02-15 | Pfizer Prod Inc | Thiazolderivate und ihre verwendung als cdk- inhibitoren |
DE60219793T2 (de) * | 2001-07-11 | 2008-01-24 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen |
US6881746B2 (en) * | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
DE60221627D1 (de) * | 2001-12-21 | 2007-09-20 | Virochem Pharma Inc | Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren |
WO2004002481A1 (fr) * | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Activateurs de la glycokinase |
TW200505894A (en) * | 2003-08-08 | 2005-02-16 | Yamanouchi Pharma Co Ltd | Tetrahydro-2H-thiopyran-4-carboxamide derivative |
BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
JP2009500377A (ja) * | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー/エス | ジシクロアルキルウレア型グルコキナーゼ活性化剤 |
-
2002
- 2002-12-19 AU AU2002351748A patent/AU2002351748B2/en not_active Ceased
- 2002-12-19 WO PCT/DK2002/000880 patent/WO2003055482A1/fr active Application Filing
- 2002-12-19 US US10/323,290 patent/US20030171411A1/en not_active Abandoned
- 2002-12-19 PL PL02370989A patent/PL370989A1/xx not_active Application Discontinuation
- 2002-12-19 MX MXPA04006048A patent/MXPA04006048A/es active IP Right Grant
- 2002-12-19 RU RU2004122407/04A patent/RU2374236C2/ru not_active IP Right Cessation
- 2002-12-19 KR KR1020047009841A patent/KR101018318B1/ko not_active IP Right Cessation
- 2002-12-19 BR BR0215212-6A patent/BR0215212A/pt not_active IP Right Cessation
- 2002-12-19 EP EP10181515A patent/EP2305648A1/fr not_active Withdrawn
- 2002-12-19 CN CNB028275012A patent/CN100506807C/zh not_active Expired - Fee Related
- 2002-12-19 CA CA002471049A patent/CA2471049A1/fr not_active Abandoned
- 2002-12-19 UA UA20040604430A patent/UA84390C2/ru unknown
- 2002-12-19 HU HU0402309A patent/HUP0402309A3/hu unknown
- 2002-12-19 EP EP20020787463 patent/EP1458382A1/fr not_active Withdrawn
- 2002-12-19 CZ CZ2004747A patent/CZ2004747A3/cs unknown
- 2002-12-19 IL IL16262002A patent/IL162620A0/xx unknown
- 2002-12-19 JP JP2003556060A patent/JP2005518391A/ja not_active Withdrawn
-
2004
- 2004-07-20 NO NO20043116A patent/NO20043116L/no not_active Application Discontinuation
-
2010
- 2010-08-06 JP JP2010178083A patent/JP2011006435A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
IL162620A0 (en) | 2005-11-20 |
CN100506807C (zh) | 2009-07-01 |
CA2471049A1 (fr) | 2003-07-10 |
WO2003055482A1 (fr) | 2003-07-10 |
UA84390C2 (ru) | 2008-10-27 |
RU2374236C2 (ru) | 2009-11-27 |
AU2002351748B2 (en) | 2009-07-09 |
HUP0402309A3 (en) | 2008-09-29 |
JP2005518391A (ja) | 2005-06-23 |
RU2004122407A (ru) | 2005-04-10 |
KR20040075900A (ko) | 2004-08-30 |
US20030171411A1 (en) | 2003-09-11 |
CZ2004747A3 (cs) | 2004-11-10 |
MXPA04006048A (es) | 2004-09-27 |
KR101018318B1 (ko) | 2011-03-04 |
BR0215212A (pt) | 2004-12-07 |
CN1658871A (zh) | 2005-08-24 |
JP2011006435A (ja) | 2011-01-13 |
EP2305648A1 (fr) | 2011-04-06 |
HUP0402309A2 (hu) | 2005-02-28 |
PL370989A1 (en) | 2005-06-13 |
EP1458382A1 (fr) | 2004-09-22 |
AU2002351748A1 (en) | 2003-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20043116L (no) | Amidderivater som GK-aktivatorer | |
DK1549638T3 (da) | Indol-3-carboxamider som glucokinase (GK) aktivatorer | |
DK1572670T3 (da) | 5-substitueret-pyrazin eller -pyridin-glucokinaseaktivatorer | |
NO20050665L (no) | Pyrrolidonderivater som MAOE inhibitoere | |
ATE319451T1 (de) | Tetrahydrochinolin-derivate | |
DK1458685T3 (da) | Substituerede phenylderivater | |
NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
ATE312827T1 (de) | 3-substituierte-4-pyrimidonderivate | |
DK1414803T3 (da) | Pyrazolylcarboxanilider som fungicider | |
NO20035634L (no) | Diamin-derivater | |
DE60204857D1 (de) | Flüssigkeitszerstäuber | |
DE60134470D1 (de) | Para-amin substituierte phenylamid glukokinase activatoren | |
NO20033618L (no) | Ftalayinon-piperidino-derivater som PDE-4-inhibitorer | |
DE60234850D1 (de) | Kühlschrank | |
NO20033353D0 (no) | Karotenoid biosyntese | |
EE200300447A (et) | Asendatud bensofuraan-2-karboksamiidide derivaadid | |
DK1399355T3 (da) | Styringsenhed | |
NO20035440D0 (no) | Pyrrolidinderivater som faktor-XA-inhibitorer | |
NO20040860L (no) | Farmasoytisk sammensetning som innbefatter lumiracoxib | |
DE60223031D1 (de) | Arylpiperazin gebundene tetrahydroindolonderivate | |
NO20033234L (no) | Karotenoider som antihypertensjonsmidler | |
FI20011507A0 (fi) | Uusia yhdisteitä | |
ATE382601T1 (de) | Substituierte 4-aminocyclohexanolderivate | |
FI20011896A (fi) | Tuloilmalaite | |
DE60202381D1 (de) | Paroxetin-n-formyl-derivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |